India’s Cumulative COVID-19 Vaccination Coverage Exceeds 125 Cr Mark: Centre
With the administration of 73,67,230 vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has exceeded 125.75 crore (1,25,75,05,514) as through 1,30,65,773 sessions.
The ministry said that a total of 8,612 patients recovered in the last 24 hours, which has increased the cumulative tally of recovered patients to 3,40,45,666. Consequently, India’s recovery rate stands at 98.35 per cent.
A total of 9,216 new cases were reported in the last 24 hours. India’s active caseload presently stands at 99,976. Active cases constitute 0.29 per cent of the country's total positive cases, which is the lowest since March 2020.
"The testing capacity across the country continues to be expanded. The last 24 hours saw a total of 11,57,156 tests being conducted. India has so far conducted over 64.46 crore (64,46,68,082) cumulative tests," the ministry said.
The weekly positivity rate at 0.84 per cent remains less than 1 per cent for the last 19 days now. The daily positivity rate is at 0.80 per cent which remained below 2 per cent for the last 60 days and below 3 per cent for 95 consecutive days now.
Meanwhile, talking about the new COVID-19 variant, the ministry said, "Omicron cases are increasingly being reported from countries outside of South Africa and given its characteristics, it is likely to spread to more countries including India. However, the scale and magnitude of rising in cases and most importantly the severity of disease that will be caused is still not clear. Further, given the fast pace of vaccination in India and high exposure to delta variant as evidenced by high seropositivity, the severity of the disease is anticipated to be below. However, scientific evidence is still evolving."
The Health Ministry informed that the Indian government is monitoring the situation closely and is issuing suitable guidelines from time to time. Meanwhile, the scientific and medical community is geared up for developing and deploying diagnostics, carrying out genomic surveillance, generating evidence about viral and epidemiologic characteristics, and developing therapeutics.
